Abstract:Cullin-RING E3 ligases (CRLs) are the major components of ubiquitin-proteasome system, responsible for ubiquitylation and subsequent degradation of thousands of cellular proteins. CRLs play vital roles in the regulation of multiple cellular processes, including cell cycle, cell apoptosis, DNA replication, signalling transduction among the others, and are frequently dysregulated in many human cancers. The discovery of specific neddylation inhibitors, represented by MLN4924, has validated CRLs as promising targets for anti-cancer therapies with a growing market. Recent studies have focused on the discovery of the CRLs inhibitors by a variety of approaches, including high through-put screen, virtual screen or structure-based drug design. The field is, however, still facing the major challenging, since CRLs are a large multi-unit protein family without typical active pockets to facilitate the drug design, and enzymatic activity is mainly dependent on undruggable protein-protein interactions and dynamic conformation changes. Up to now, most reported CRLs inhibitors are aiming at targeting the F-box family proteins (e.g., SKP2, β-TrCP and FBXW7), the substrate recognition subunit of SCF E3 ligases. Other studies reported few small molecule inhibitors targeting the UBE2M-DCN1 interaction, which specifically inhibits CRL3/CRL1 by blocking the cullin neddylation. On the other hand, several CRL activators have been reported, such as plant auxin and immunomodulatory imide drugs, thalidomide. Finally, proteolysis-targeting chimeras (PROTACs) has emerged as a new technology in the field of drug discovery, specifically targeting the undruggable protein-protein interaction. The technique connects the small molecule that selectively binds to a target protein to a CRL E3 via a chemical linker to trigger the degradation of target protein. The PROTAC has become a hotspot in the field of E3-ligase-based anti-cancer drug discovery.

Modulation of Cullin-RING E3 ubiquitin ligase-dependent ubiquitination by small molecule compounds

Targeting Cullin-RING Ubiquitin Ligases and the Applications in PROTACs

Suramin Inhibits Cullin-Ring E3 Ubiquitin Ligases

Cullin-RING ligases in regulation of autophagy

Targeting Cullin-RING E3 ligases for anti-cancer therapy:efforts on drug discovery

CAND1 inhibits Cullin-2-RING ubiquitin ligases for enhanced substrate specificity

Cullin-RING Ligases as attractive anti-cancer targets.

Cullin–RING ubiquitin E3 ligase regulation by the COP9 signalosome

Cullin-RING E3 Ubiquitin Ligases: Bridges to Destruction.

Gln40 deamidation blocks structural reconfiguration and activation of SCF ubiquitin ligase complex by Nedd8

CUL5-ARIH2 E3-E3 ubiquitin ligase structure reveals cullin-specific NEDD8 activation

Cullin-RING ligases employ geometrically optimized catalytic partners for substrate targeting

A Potent Small-Molecule Inhibitor of the DCN1-UBC12 Interaction That Selectively Blocks Cullin 3 Neddylation

UBE2G1 governs the destruction of cereblon neomorphic substrates.

TRAF2 associates with cullin neddylation complex assembly

UBE2G1 Governs the Destruction of Cereblon Neomorphic Substrates

Basis for metabolite-dependent Cullin-RING ligase deneddylation by the COP9 signalosome

Noncanonical assembly, neddylation and chimeric cullin–RING/RBR ubiquitylation by the 1.8 MDa CUL9 E3 ligase complex

CRL3s: The BTB-CUL3-RING E3 Ubiquitin Ligases

High-Affinity Peptidomimetic Inhibitors of the DCN1-UBC12 Protein-Protein Interaction.

SIRT7 deacetylates DDB1 and suppresses the activity of the CRL4 E3 ligase complexes.